Highlights Cereno Scientific AB

Equities

CRNO B

SE0008241558

Market Closed - Nasdaq Stockholm Other stock markets 16:29:43 05/06/2024 BST			5-day change	1st Jan Change
4.4 ^SEK	+1.38%		+2.85%	-3.83%

05-23	Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-02	Cereno Scientific AB Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate	04-11	MT
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment	04-10	MT
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014	04-10	CI
Cereno Scientific Receives Patent Expansion in Europe	04-09	MT
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate	03-22	MT
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH	03-21	CI
Cereno Scientific Appoints Don De Bethizy as Board of Directors	03-14	CI
Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH	03-06	CI
Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH	02-29	CI
Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH	02-21	CI
Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension	01-31	CI
Cereno Scientific Pens Contact with CordenPharma for Scaled Manufacturing of Hypertension Drug	01-11	MT
Cereno Scientific Submits Request to the FDA for "Compassionate Use" of CS1 for Treatment of Patients with Rare Disease Pulmonary Arterial Hypertension	01-04	CI
Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH	12-21	CI
Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting	12-13	CI
Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585	12-12	CI
Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study	12-01	CI
Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family	11-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cereno Scientific AB

Equities

CRNO B

SE0008241558

Highlights

Filters